Welcome to our dedicated page for ZENYF news (Ticker: ZENYF), a resource for investors and traders seeking the latest updates and insights on ZENYF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZENYF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZENYF's position in the market.
ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC Pink:ZENYF) announced its preliminary production plan for a biocidal coating in response to growing demand in the PPE and air filtration markets. Transitioning from bench scale to pilot scale, ZEN is increasing production capacity to meet orders from Trebor RX and new customers. By June 2021, ZEN aims for a monthly coating capacity of 32 million masks, escalating to 800 million masks at the industrial scale by November. The company emphasizes efficient investment and supply chain optimization to maximize current opportunities and maintain future growth.
ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTCPINK:ZENYF) announced successful testing results for its graphene-based compound against antimicrobial-resistant bacteria, including MRSA. The compound demonstrated 99.9% effectiveness against four gram-positive and nine gram-negative bacteria. The minimum inhibitory concentration (MIC) was extremely low, below 1 µg/ml. The CEO highlighted the potential global health impact of antimicrobial resistance (AMR) and the need for novel treatments. ZEN is pursuing partnerships and regulatory consultations to expedite the development of this promising therapeutic solution.
ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC Pink:ZENYF) has signed an Implementation Agreement with Constance Lake First Nation to advance the Albany Graphite Project. This agreement outlines governance and responsibilities for a long-term partnership aimed at accelerating the development of the Albany Graphite deposit. It establishes a collaborative committee to tackle project-related issues, including environmental assessment and community benefits. Leaders from both organizations expressed optimism about enhancing economic development and sustainability for the community through this partnership.
ZEN Graphene Solutions Ltd. (TSXV:ZEN)(OTC Pink:ZENYF) announced that Trebor Rx Corp.'s surgical masks featuring ZEN's biocidal coating have passed Health Canada testing, classifying them as level 2 medical devices. This milestone enables Trebor to start marketing the masks, with production expected to ramp up in April due to rising demand. Both companies anticipate significant growth potential from this innovative product aimed at enhancing protection against pathogens such as COVID-19.
ZEN Graphene Solutions Ltd. (TSXV:ZEN)(OTC PINK:ZENYF) announced successful phase 2 cytotoxicity testing of its graphene-based compound. The study, conducted by Nucro-Technics, reported no adverse effects after seven days of repeated dosing, even at high concentrations effective against pathogens. The company plans to initiate a 14-day repeated dose toxicity preclinical study, advancing towards phase 1 human clinical trials. ZEN’s technology aims to address antimicrobial resistance, a major global public health threat.
ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has been recognized as a Venture 50 company by the TSX Venture Exchange for 2020, highlighting top performers based on market capitalization growth, share price appreciation, and trading volume. Executive Chairman Dr. Francis Dubé emphasized the company's focus on developing graphene-based technologies, including a biocidal coating with potential applications against COVID-19 and in various biomedical fields. ZEN also possesses the Albany Graphite Project, enhancing its competitive edge in the graphene market.
ZEN Graphene Solutions Ltd. (TSX-V:ZEN, OTC:ZENYF) announced promising initial phase 2 results from a 7-day repeated dose safety study of its graphene-based compound, indicating no concerns at tested doses (50, 250, and 1,000 mg/kg). The compound's high dose was significantly greater than the Minimum Inhibitory Concentration, encouraging further development. ZEN aims to proceed to Phase 1 human trials after final histopathology results. The company focuses on utilizing its biocidal compound for pharmaceutical applications, demonstrating potential for infectious disease treatment.